|
Court: Generics Exempt Product Fees; But PDUFA V Removes This Loophole
A federal court has ruled that drugmakers shouldn’t have to pay product fees for drugs with an approved generic, even when that generic isn’t actively marketed, but this precedent will be short lived as the fifth authorization of the Prescription Drug User Fee Act (PDUFA) closes this loophole.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Related Articles
Union Suit Claims Warner Chilcott Schemed to Stall Generics, Push Weaker Product Teva Prepping for Potential $2 Billion Loss in Protonix Patent FlapLawmakers to SCOTUS: Congress Purposely Did Not Preempt Drugmakers From State SuitsPhRMA Joins Generic Makers in Calling for SCOTUS Reversal of Mutual Decision
|
Subscribe
Archives